Understanding the varied effects of neurofibromatosis type 1 to improve treatment and risk assessment
Modeling neurofibromatosis-1 disease heterogeneity to optimize risk assessment and treatment
This study is looking at neurofibromatosis type 1 (NF1) to understand how different genes and other factors affect the symptoms people experience, so we can create better, personalized treatments just for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11134859 on NIH RePORTER |
What this research studies
This research focuses on neurofibromatosis type 1 (NF1), a genetic condition that leads to a wide range of neurological issues and tumors. The project aims to identify the genetic and molecular factors that contribute to the diverse symptoms experienced by patients with NF1. By analyzing how these factors interact with both internal and external influences, the research seeks to develop personalized treatment strategies that are more effective for each individual. Patients may benefit from improved risk assessments and tailored therapies based on their unique disease characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with neurofibromatosis type 1, particularly children and young adults experiencing neurological problems or tumors.
Not a fit: Patients with other unrelated genetic conditions or those who do not have neurofibromatosis type 1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with neurofibromatosis type 1.
How similar studies have performed: Previous research has shown promise in understanding genetic conditions through personalized approaches, suggesting potential for success in this area as well.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Gutmann, David H — Washington University
- Study coordinator: Gutmann, David H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.